



Xler8tr

PRESS RELEASE PRESS RELEASE

XLER8TR EMERGES FROM STEALTH

Xler8tr announced its emergence from stealth today.

After initial test marketing conducted in January 2017 amongst global pharmaceutical companies, Xler8tr went into stealth to develop its 6 month course based around four cores:

- Commercial
- Funding
- Financial
- Legal

During its time in stealth Xler8tr formed strategic partnerships with some of the leading global advisory businesses together with public sector bodies with the aim of offering a program able to advance the commercials of very early stage and interesting science to the articulation of a commercialization plan together with support data room, even from entities that have not incorporated prior to entry onto the course.

These early stage Prospects/projects will be sponsored by leading global pharmaceutical and life science enterprises who will also mentor the science while Xler8tr advances the commercials.

Prospects will enjoy the further advantage of being mentored by some of the leading global advisory businesses, together with sector good and great and public sector bodies. Being on the Xler8tr course gives Prospects the opportunity to maximize their opportunities to raise further dilutive and non-dilutive/ grant funding as well as early stage commercial partnerships.

1 May 2017

About Xler8tr

The Cambridge based pharmaceutical / life sciences accelerator with strategic partnerships with leading global advisory businesses advances the commercials of very early stage (pre POC) science through incorporation creating independent and transportable IT, legal and management accounting infrastructure vested with IP. Xler8tr creates a digital presence and initial branding. At the end of the 6 month course prospects articulate their commercialisation plans with supporting data room to attract next stage dilutive and non-dilutive funding.